Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Allarity Therapeutics, Inc.

< Previous 1 2 Next >
News headline image
Allarity Therapeutics Granted Japanese Patent for Stenoparib DRP® Companion Diagnostic, Further Strengthening Stenoparib Development
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLR
News headline image
Allarity Therapeutics Announces Strategic Capital Allocation for Filing of SPAC Registration Statement
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLR
News headline image
Allarity Therapeutics Reports Second Quarter 2026 Results and Completion of the Phase 3-Ready Stenoparib Manufacturing Campaign
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLR
News headline image
Allarity Therapeutics Announces CLIA Certification, Clearing the Path for Advancing DRP® Testing for FDA Registration
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLR
News headline image
Allarity Therapeutics Announces the Grant of Essential U.S. Patent for Its Stenoparib DRP® Companion Diagnostic
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLR
News headline image
Allarity Therapeutics to Present Trial-in-Progress Poster on Phase 2 Stenoparib Trial at ESMO Gynaecological Cancers Congress 2026
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLR
News headline image
Allarity Therapeutics Reports First Quarter 2026 Results and Continued Stenoparib Development in Multiple Cancers
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLR
News headline image
Allarity Therapeutics CEO to Present at Precision Medicine Forum Europe 2026 in Stockholm
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLR
News headline image
Allarity Therapeutics Advances Stenoparib Toward Pivotal Development with Phase 3 Manufacturing Campaign
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLR
News headline image
Allarity Therapeutics Announces that the Stenoparib DRP® Test Has Received a Notice of Allowance from the US Patent and Trademark Office
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLR
News headline image
Allarity Therapeutics Presents Two AACR 2026 Posters Highlighting Stenoparib’s Potential in Colorectal Cancer as well as New Predictive Data Linking DRP® and Overall Survival in Ovarian Cancer
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLR
News headline image
Allarity Therapeutics Reports Full Year 2025 Financial Results and Corporate Progress
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLR
News headline image
Allarity Therapeutics Closes $20 Million Financing to Accelerate the Advance of Stenoparib Toward FDA Approval and Commercialization
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLR
News headline image
Allarity Therapeutics Doses First Patients in VA-Funded Phase 2 Trial Focused on Small Cell Lung Cancer with High Unmet Need
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLR
News headline image
Allarity Therapeutics announces that its collaborative Phase 2 trial with the United States Veteran’s Administration Combining Stenoparib with Temozolomide in Relapsed Small Cell Lung Cancer is Now Open for Enrollment
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLR
News headline image
Allarity Therapeutics Issues 2025 End of Year CEO Letter to Shareholders
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLR
News headline image
Allarity Therapeutics Provides Third Quarter 2025 Financial Results and Provides Business Updates
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLR
News headline image
Allarity Therapeutics Presents New Phase 2 Clinical Data for Stenoparib/2X-121 Showing Landmark Median Overall Survival Has Now Surpassed 25 Months
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLR
News headline image
Allarity Therapeutics CEO to Present at Biomarkers & Precision Medicine 2025
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLR
News headline image
Allarity Therapeutics Granted FDA Fast Track Designation for Stenoparib for the Treatment of Advanced Ovarian Cancer
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLR
News headline image
Allarity Therapeutics Provides Second Quarter 2025 Update, Highlighting Clinical Progress, IP Expansion, and New Partnerships
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLR
News headline image
Allarity Therapeutics Announces New Licensing and Laboratory Services Agreement to Expand DRP® Platform Utilization
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLR
News headline image
Allarity Therapeutics Announces Appointment of Jeff Ervin as Chief Financial Officer
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLR
News headline image
Allarity Therapeutics Receives Australian Patent Acceptance Notice for Stenoparib DRP® Companion Diagnostic
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLR
News headline image
Allarity Therapeutics Announces Dosing of Second Patient in New Phase 2 Trial of Stenoparib in Advanced Ovarian Cancer
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLR
News headline image
Allarity Therapeutics Announces Changes to Board of Directors
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLR
News headline image
Allarity Therapeutics Announces Research Collaboration with Indiana Biosciences Research Institute to Further Advance Understanding of Stenoparib’s Unique, Dual Therapeutic Mechanism of Action
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLR
News headline image
Allarity Therapeutics Announces First Patient Enrolled in New Phase 2 Clinical Trial Protocol of Stenoparib in Advanced Ovarian Cancer
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLR
News headline image
Allarity Therapeutics Announces Participation in Pharma Partnering Summit US
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLR
News headline image
Allarity Therapeutics Provides First Quarter 2025 Update, Highlighting Continued Stenoparib Benefit and Upcoming Trial Enrollment
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLR
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.